AU2017266686B2 - Markers selectively deregulated in tumor-infiltrating regulatory T cells - Google Patents

Markers selectively deregulated in tumor-infiltrating regulatory T cells Download PDF

Info

Publication number
AU2017266686B2
AU2017266686B2 AU2017266686A AU2017266686A AU2017266686B2 AU 2017266686 B2 AU2017266686 B2 AU 2017266686B2 AU 2017266686 A AU2017266686 A AU 2017266686A AU 2017266686 A AU2017266686 A AU 2017266686A AU 2017266686 B2 AU2017266686 B2 AU 2017266686B2
Authority
AU
Australia
Prior art keywords
cells
tumor
cell
expression
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017266686A
Other languages
English (en)
Other versions
AU2017266686A1 (en
Inventor
Sergio Abrignani
Massimiliano Pagani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Checkmab SRL
Original Assignee
Checkmab SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkmab SRL filed Critical Checkmab SRL
Publication of AU2017266686A1 publication Critical patent/AU2017266686A1/en
Application granted granted Critical
Publication of AU2017266686B2 publication Critical patent/AU2017266686B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
AU2017266686A 2016-05-16 2017-05-15 Markers selectively deregulated in tumor-infiltrating regulatory T cells Active AU2017266686B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16169791.7 2016-05-16
EP16169791 2016-05-16
EP16198724.3 2016-11-14
EP16198724 2016-11-14
PCT/EP2017/061642 WO2017198631A1 (en) 2016-05-16 2017-05-15 Markers selectively deregulated in tumor-infiltrating regulatory t cells

Publications (2)

Publication Number Publication Date
AU2017266686A1 AU2017266686A1 (en) 2019-01-03
AU2017266686B2 true AU2017266686B2 (en) 2023-03-09

Family

ID=58772864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017266686A Active AU2017266686B2 (en) 2016-05-16 2017-05-15 Markers selectively deregulated in tumor-infiltrating regulatory T cells

Country Status (9)

Country Link
US (3) US20190391152A1 (enExample)
EP (2) EP3458473B8 (enExample)
JP (3) JP7358047B2 (enExample)
KR (1) KR102623927B1 (enExample)
CN (1) CN109715653A (enExample)
AU (1) AU2017266686B2 (enExample)
ES (1) ES2922525T3 (enExample)
MX (2) MX395142B (enExample)
WO (1) WO2017198631A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
PT3431105T (pt) 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods of activating dysfunctional immune cells and treatment of cancer
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
CN110187107A (zh) * 2019-04-26 2019-08-30 温州医科大学 一种基于肿瘤组织浸润免疫细胞特征建立的结直肠癌预后评估装置及方法
JP2023514441A (ja) * 2020-02-20 2023-04-05 アンスティテュ・クリー 機能性疾患特異的制御性ｔ細胞を同定する方法
JP2023515981A (ja) * 2020-02-26 2023-04-17 ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ペプチジルグリシンαアミド化モノオキシゲナーゼ（ＰＡＭ）を決定する方法および診断目的でのその使用
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
CN113933508A (zh) * 2020-07-13 2022-01-14 上海吉凯基因医学科技股份有限公司 人batf基因的用途及相关产品
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
PE20240638A1 (es) 2021-07-14 2024-03-27 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
TWI920354B (zh) 2021-07-27 2026-04-01 美商艾伯維有限公司 抗ｃｃｒ８抗體
CN114381528B (zh) * 2022-02-14 2024-06-28 天津市泌尿外科研究所 Mettl7a基因及其表达产物在诊断和治疗肿瘤中的用途
KR102492241B1 (ko) * 2022-02-25 2023-01-30 전남대학교산학협력단 Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도
KR20240113400A (ko) * 2023-01-11 2024-07-22 한국과학기술원 종양 내 Treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물
CN116496417B (zh) * 2023-06-27 2023-10-10 北京市肿瘤防治研究所 含有膜型il7的融合蛋白及t细胞
CN117079710B (zh) * 2023-08-18 2024-05-31 上海爱谱蒂康生物科技有限公司 生物标志物及其在预测和/或诊断utuc肌肉浸润中的应用
CN117587014B (zh) * 2023-11-24 2025-01-24 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN117625792B (zh) * 2024-01-23 2024-04-16 杭州华得森生物技术有限公司 用于胃癌诊断和预后判断的生物标志物及其应用
CN118064595B (zh) * 2024-04-17 2024-08-02 中山大学附属第六医院 一种预测结直肠癌肝转移的生物标志物及其应用
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075A (en) 1847-04-17 Improvement in cultivators
US109A (en) 1836-12-15 Erawijtg
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
AU8669598A (en) * 1997-07-29 1999-02-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine receptor ccr8 dna and uses thereof
AR016681A1 (es) * 1997-11-13 2001-07-25 Schering Corp Deplecion de celulas th2; composiciones; metodos
CA2513143A1 (en) * 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
JP2008072939A (ja) * 2006-09-21 2008-04-03 Fujifilm Corp 多発性骨髄腫の検出方法および抑制方法
US20100292303A1 (en) * 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
WO2013131010A2 (en) * 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
WO2015017537A2 (en) * 2013-07-30 2015-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Colorectal cancer recurrence gene expression signature
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bhairavabhotla, R. et al., 'Transcriptome profiling of human FoxP3+regulatory T cells', Human Immunology (2015-12-10), vol. 77, no. 2, pages 201 - 213, doi:10.1016/J.HUMIMM.2015.12.004 *
Marabelle, A. et al., 'Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", Journal of Clinical Investigation, American society for clinical investigation', (2013-06-01), vol. 123, no. 6, pages 2447 - 2463 *
Plitas, G. et al., 'Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target', Cancer Research (2016-02-15), vol. 76. *
Takeuchi, Y. et al., 'Roles of regulatory T cells in cancer immunity", International Immunology' (2016-05-09), vol. 28, no. 8, pages 401 - 409, doi:10.1093/intimm/dxw025. *

Also Published As

Publication number Publication date
MX2018013952A (es) 2019-06-24
KR102623927B1 (ko) 2024-01-12
MX395142B (es) 2025-03-25
MX2022010703A (es) 2022-09-27
BR112018073414A2 (pt) 2019-08-27
ES2922525T3 (es) 2022-09-16
EP3458473A1 (en) 2019-03-27
EP4092045A1 (en) 2022-11-23
WO2017198631A1 (en) 2017-11-23
JP2023113918A (ja) 2023-08-16
US20230375555A1 (en) 2023-11-23
KR20190006009A (ko) 2019-01-16
US20250251401A1 (en) 2025-08-07
JP7358047B2 (ja) 2023-10-10
JP2025172069A (ja) 2025-11-20
AU2017266686A1 (en) 2019-01-03
CA3023980A1 (en) 2017-11-23
EP3458473B8 (en) 2022-08-17
EP3458473B1 (en) 2022-04-13
US20190391152A1 (en) 2019-12-26
CN109715653A (zh) 2019-05-03
US20260056201A9 (en) 2026-02-26
US12247982B2 (en) 2025-03-11
JP2019518452A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
US12247982B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
JP7843113B2 (ja) Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法
JP2023529026A (ja) Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用
WO2018183921A1 (en) Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019070755A1 (en) METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
WO2021150925A1 (en) Uses of biomarkers for improving immunotherapy
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US20210347847A1 (en) Therapeutic targeting of malignant cells using tumor markers
JP2023514441A (ja) 機能性疾患特異的制御性ｔ細胞を同定する方法
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
WO2019014665A1 (en) MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
KR20220031069A (ko) 항-종양 치료의 효과를 진단하기 위한 방법
JP2020536111A (ja) リンパ腫を処置する方法
CA3023980C (en) Markers selectively deregulated in tumor-infiltrating regulatory t cells
JP7856627B2 (ja) ガンを予防及び処置するための方法及び組成物
BR112018073414B1 (pt) Métodos in vitro para determinar o prognóstico de um indivíduo com um tumor sólido, e para monitorar a eficácia de um tratamento terapêutico de um tumor sólido, e, método para identificar uma molécula que atua como uma molécula antitumoral contra um tumor sólido
JP2025540193A (ja) 卵巣がんを診断及び治療するための方法
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy
HK40022696A (en) Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
HK40022696B (en) Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)